Nanotech investment will have payoff

A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Oncology and CNS diseases in particular will be a target for nanotech drug developers, which include, Flamel Technologies, Sandvik and Orthovita. Intellectual property and the attitudes of agencies faced with regulating nanotech trials will prove to be challenges, however. Report

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.